Rite Aid reported third-quarter earnings and sales that exceeded analysts’ expectations.
The pharmacy retail company’s adjusted earnings for the quarter came in at 40 cents a share, compared to 2 cents expected by analysts.
Revenue rose +12% year-over-year to $6.12 billion, also topping analysts’ forecast of $5.84 billion.
For its fiscal 2021, Rite Aid hiked its revenue guidance to between $23.9 billion and $24.2 billion (from its prior projection of $23.5 billion and $24 billion). It expects same- store sales growth to range between 3.5% and 4.5%, (from its prior guidance of between 3% and 4%. ).
"We are pleased with our third-quarter performance as we continue to grow our business and achieve major physical and digital milestones through our RxEvolution strategy," said Rite Aid CEO Heyward Donigan. Donigan also mentioned the launch of the company’s new brand and logo, and said that the company has made “substantial progress” in evolving its merchandise mix to support whole health.
RADCQ moved below its 50-day moving average on February 22, 2024 date and that indicates a change from an upward trend to a downward trend. In of 29 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
The Aroon Indicator for RADCQ entered a downward trend on March 04, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 66 cases where RADCQ's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on March 13, 2024. You may want to consider a long position or call options on RADCQ as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for RADCQ just turned positive on March 13, 2024. Looking at past instances where RADCQ's MACD turned positive, the stock continued to rise in of 38 cases over the following month. The odds of a continued upward trend are .
Following a +11 3-day Advance, the price is estimated to grow further. Considering data from situations where RADCQ advanced for three days, in of 288 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RADCQ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (11.388). P/E Ratio (0.000) is within average values for comparable stocks, (152.508). RADCQ's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.997). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. RADCQ's P/S Ratio (0.000) is slightly lower than the industry average of (0.772).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RADCQ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
an operator of retail drug stores
Industry DrugstoreChains